GABRA1-Related Epilepsy — a spectrum of autosomal dominant epilepsy syndromes caused by heterozygous pathogenic variants in GABRA1 (gamma-aminobutyric acid type A receptor subunit alpha1 gene, chromosome 5q34); GABRA1 encodes the alpha-1 subunit of GABA-A receptors — the predominant inhibitory ionotropic receptor in the adult brain; GABA-A receptors are pentameric chloride ion channels assembled from subunit combinations, with the alpha-1 subunit being the most abundant GABA-A subunit in the central nervous system — particularly concentrated at GABAergic synapses on pyramidal neurons and inhibitory interneurons; GABRA1 pathogenic variants reduce GABA-A mediated inhibition, increasing neuronal excitability and seizure propensity across a phenotypic spectrum that includes: (1) Childhood Absence Epilepsy (CAE) with autosomal dominant inheritance — brief staring spells with absence seizures, 3 Hz spike-wave discharges on electroencephalography, typically onset between 4 and 10 years, often drug-responsive to ethosuximide or valproate with high rates of remission in adolescence; (2) Juvenile Myoclonic Epilepsy (JME) — myoclonic jerks on awakening, generalized tonic-clonic seizures, photosensitivity, and typical adolescent onset with lifelong seizure susceptibility requiring long-term antiepileptic drug therapy; (3) Dravet-like GABRA1 Epileptic Encephalopathy — rare de novo severe GABRA1 variants producing fever-sensitive seizures, drug resistance, developmental regression, and intellectual disability resembling the SCN1A Dravet syndrome phenotype but caused by GABA-A receptor dysfunction — as a family of conditions with shared molecular etiology but divergent clinical severity, pharmacological management requirements, and lifelong monitoring obligations at the intersection of pediatric epileptology, neurogenetics, and epilepsy care coordination.
GABRA1 care technology platforms — encompassing the molecular genetics laboratories where GABRA1 sequencing and deletion/duplication analysis establish variant identity and inheritance pattern; the seizure diary and absence episode counting platforms that are the primary outcome tracking tools for CAE — where absence seizure frequency (often dozens of brief daily episodes), treatment response to ethosuximide or valproate, and breakthrough absence documentation determine medication adequacy and guide dose titration; the EEG surveillance scheduling tools and neurophysiology result platforms coordinating the annual 3 Hz spike-wave and photoparoxysmal response monitoring required for JME and CAE management; the photosensitivity management platforms tracking screen exposure documentation, sunglasses use, and flashing stimuli avoidance compliance for JME-affected individuals; the valproate safety monitoring systems coordinating CBC, LFT, and weight surveillance for GABRA1 patients on valproate; the sleep diary and sleep hygiene adherence platforms critical for JME management — where sleep deprivation is the primary seizure trigger; the sodium channel blocker contraindication documentation systems ensuring carbamazepine and lamotrigine are flagged as medications to avoid in GABRA1 epilepsy; the driving restriction documentation platforms coordinating country-specific seizure-free period requirements; and the lifestyle trigger diary systems tracking alcohol, sleep deprivation, and stress patterns as JME seizure precipitants — must maintain availability and performance standards matched to the absence episode counting urgency, photosensitivity management requirements, and lifelong epilepsy care coordination demands of modern GABRA1 disorder management. This guide explains why GABRA1 care tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the absence diary urgency and JME lifestyle management requirements of contemporary GABRA1 epilepsy care.
Why GABRA1-Related Epilepsy Tech Platforms Require Specialized Monitoring Attention
GABRA1 epilepsy management is defined by several clinically urgent platform requirements: the absence counting urgency — for CAE, absence seizures may occur dozens of times daily; each brief episode is clinically imperceptible to observers who are not specifically watching and requires real-time counting platforms for accurate frequency determination that drives ethosuximide dose adjustment; the JME lifestyle urgency — JME is a lifelong epilepsy syndrome where sleep deprivation, alcohol, and stress are primary seizure triggers and photosensitivity is a risk factor for visually-induced seizures; the photosensitivity and lifestyle trigger management platforms must be consistently accessible for patient self-monitoring documentation; the sodium channel blocker contraindication urgency — carbamazepine and lamotrigine may worsen seizures in GABRA1 epilepsy including precipitating status epilepticus, creating a patient safety requirement that medication contraindication documentation systems remain continuously accessible; the valproate monitoring urgency — JME treatment with valproate requires ongoing CBC, LFT, and weight monitoring for hepatotoxicity, thrombocytopenia, and weight gain surveillance, making laboratory monitoring platform availability a treatment safety requirement; and the driving restriction urgency — country-specific seizure-free period requirements for driving licensure require accurate seizure diary documentation that is maintained only when seizure diary platforms remain available across long follow-up intervals.
Molecular genetic testing platforms establish GABRA1 variant identity and guide syndrome classification. Sequencing distinguishes CAE, JME, and Dravet-like encephalopathy phenotypes and establishes inheritance pattern for family counseling. Monitor at 1-minute intervals during laboratory hours.
Absence seizure diary platforms capture the high-frequency, brief daily episodes that are the primary CAE outcome measure. Absence episode counting — often 20–100 brief episodes per day — requires continuous platform availability to maintain the daily frequency logs that determine ethosuximide and valproate dosing adequacy. Monitor at 1-minute intervals during clinical hours.
Photosensitivity management platforms document JME trigger avoidance compliance. Screen time, sunglasses use, and flashing stimuli exposure documentation require platform availability for patient self-reporting between clinical visits. Monitor at 1-minute intervals during clinical hours.
Valproate safety monitoring platforms coordinate the laboratory surveillance required for JME treatment safety. CBC, LFT, weight monitoring, and blood valproate levels at prescribed intervals require scheduling and result platform availability. Monitor at 1-minute intervals during clinical hours.
Sodium channel blocker contraindication documentation systems protect GABRA1 patients from seizure-worsening medications. Carbamazepine and lamotrigine contraindication flags must be accessible to prescribers at every clinical encounter and pharmacy interaction. Monitor continuously.
What to Monitor on a GABRA1-Related Epilepsy Tech Platform
Molecular Genetic Testing — GABRA1 Variant Identification and Syndrome Classification
Monitor GABRA1 gene sequencing records (full coding sequence analysis — pathogenic variant identification and ACMG classification; de novo vs. familial variant determination — trio analysis for Dravet-like GABRA1 encephalopathy; dominant missense variant characterization for CAE and JME — protein domain localization, functional prediction; large deletion and duplication analysis by chromosomal microarray or MLPA; variant registry cross-reference — published GABRA1 variants in ClinVar, LOVD, and literature; phenotype-genotype correlation documentation — variant type predicting CAE vs. JME vs. encephalopathy trajectory; parental testing and family cascade records), genetic counseling records (autosomal dominant inheritance counseling for CAE and JME — 50% offspring recurrence risk; de novo counseling for Dravet-like GABRA1 encephalopathy; family cascade testing coordination for at-risk relatives; reproductive options counseling; syndrome prognosis counseling — CAE often remits, JME is lifelong, encephalopathy carries intellectual disability risk; phenotypic variability counseling within GABRA1 families — variable expressivity of seizure type), and variant functional interpretation records (published functional data review — patch-clamp studies, surface expression assays; phenotype reclassification records if variant functional status changes; molecular genetics multidisciplinary team review records) at 1-minute intervals during laboratory hours. Alert immediately — GABRA1 molecular testing platform failures during evaluation of a 7-year-old girl presenting with teacher-reported episodes of staring and lip-smacking lasting 5–10 seconds occurring 15–20 times daily, with 3 Hz spike-wave discharges on EEG confirming childhood absence epilepsy — when GABRA1 sequencing identifies a familial dominant missense variant establishing genetic CAE, guides ethosuximide prescription as the preferred narrow-spectrum AED over valproate in a prepubertal girl, triggers cascade testing of her mother who reports "spacing out" episodes in childhood that she had not previously attributed to epilepsy, and avoids empirical carbamazepine that could catastrophically aggravate her GABRA1 absence epilepsy.
Absence Seizure Diary — CAE Primary Outcome Monitoring
Monitor daily absence episode frequency records (absence seizure counting records — daily episode count per patient or caregiver diary; episode duration documentation — typical absence 5–30 seconds; breakthrough absence documentation during apparent remission; absence cluster documentation; morning vs. afternoon frequency pattern for ethosuximide peak-effect correlation), absence video documentation records (brief video captures of observed absence episodes — eye flutter, lip-smacking, automatisms; school observation records — teacher-completed absence monitoring forms; clinical video-EEG correlation records; absence semiology documentation — eyelid myoclonia classification), ethosuximide adherence and response records (daily ethosuximide dose and frequency — weight-based dosing for pediatric patients; serum ethosuximide level monitoring records — target 40–100 μg/mL; GI side-effect diary — nausea, abdominal discomfort — dose-limiting ethosuximide tolerability documentation; absence frequency trend on current ethosuximide dose vs. pre-treatment baseline; breakthrough absence on therapeutic levels — indication for valproate addition or switch), and remission documentation records (seizure-free interval records — 2-year absence-free period as typical remission threshold; EEG normalization records coinciding with clinical remission; medication taper records and post-taper seizure surveillance; CAE to JME evolution monitoring — minority of CAE patients evolve to JME phenotype with myoclonic and GTC seizures) at 1-minute intervals during clinical hours. Alert immediately — absence diary platform failures during a scheduled follow-up visit for a 9-year-old boy with GABRA1-CAE who has been on ethosuximide for 6 months — when the seizure diary platform is the tool through which his pediatric neurologist identifies that absence frequency has declined from 25 per day at baseline to 3–4 per day on current dosing, confirming partial but incomplete treatment response that indicates the need for ethosuximide dose optimization rather than medication switch, and preventing a premature treatment change that would unnecessarily expose the child to valproate-associated weight gain and hepatotoxicity when dose adjustment of a well-tolerated agent remains the appropriate next step.
JME Seizure Diary — Myoclonic and GTC Episode Tracking
Monitor myoclonic jerk diary records (morning myoclonic jerk frequency and severity — arms affected, objects dropped, falls; time of day relative to awakening — JME myoclonus characteristically worst within 30–60 minutes of waking; myoclonic jerk severity grading — mild (awareness only) to severe (falls or injury); jerk-to-GTC escalation documentation — sequences where myoclonus progressed to generalized tonic-clonic seizures; menstrual cycle correlation for female JME patients — catamenial myoclonus exacerbation), generalized tonic-clonic seizure documentation records (GTC date, time of day, circumstances; duration and post-ictal period; injury documentation — tongue bite, fall injury; precipitant documentation — sleep deprivation, alcohol, missed dose, illness, stress; rescue medication use at each GTC — benzodiazepine administration records), valproate or levetiracetam adherence records (daily dose and schedule — valproate extended-release preferred for JME; serum valproate level monitoring records — target 50–100 μg/mL; CBC monitoring records — thrombocytopenia surveillance; LFT monitoring records — hepatotoxicity surveillance at initiation and annually; weight monitoring records — valproate weight gain — monthly weight for pediatric patients; levetiracetam adherence records — blood levels less critical but behavioral side-effect diary), and long-term JME management records (JME as lifelong epilepsy syndrome — annual review of seizure control status; medication taper attempt records with outcome — relapse rates high in JME; driving status review records; lifestyle counseling compliance documentation — sleep, alcohol, stress management) at 1-minute intervals during clinical hours.
Photosensitivity Management — JME Visual Trigger Documentation
Monitor photosensitivity diary records (screen exposure documentation — daily total screen time; television, video game, and strobe light exposure diary; flashing stimuli encounter documentation — concerts, clubs, nightlife environments, emergency vehicle lights; sunglasses use compliance diary — polarized lens use outdoors and in high-luminance environments), EEG photoparoxysmal response records (annual EEG photoparoxysmal response testing — intermittent photic stimulation protocol; frequency of flash stimulation triggering spike-wave discharge; photoparoxysmal response persistence vs. suppression on valproate or levetiracetam; medication effect on photosensitivity threshold documentation), environmental modification counseling records (school accommodation documentation — seating away from windows and flickering fluorescent lights; workplace assessment records for screen-heavy occupations; driving restriction counseling for patients with photo-triggered seizures — seizure-free requirements not met while photosensitivity persists), and patient education records (patient-completed photosensitivity self-assessment; caregiver education completion records; written photosensitivity management plan documentation) at 1-minute intervals during clinical hours.
Valproate and AED Safety Monitoring — GABRA1 Treatment Surveillance
Monitor valproate safety laboratory records (CBC monitoring records at initiation, 3 months, and annually — platelet count trend; hepatic function monitoring records — ALT, AST, bilirubin at initiation, 3 months, and annually; serum amylase and lipase records for pancreatitis surveillance; valproate blood level records — trough level documentation, therapeutic range monitoring; weight monitoring records — BMI z-score for pediatric patients on valproate; hair loss diary records — telogen effluvium documentation; teratogenicity counseling records — valproate neural tube defect risk and contraception counseling for women of childbearing potential), ethosuximide safety records (CBC monitoring for rare agranulocytosis; GI tolerance diary; SLE-like reaction documentation), and contraindication documentation records (sodium channel blocker contraindication list — carbamazepine, lamotrigine, phenytoin, oxcarbazepine flagged as medications to avoid in GABRA1 epilepsy; allergic reaction and seizure aggravation documentation if sodium channel blockers were prescribed before GABRA1 diagnosis; pharmacy alert system records — medication safety flags; emergency medical information records documenting GABRA1 diagnosis and contraindicated medications) at 1-minute intervals during clinical hours. Alert immediately — valproate monitoring platform failures preventing laboratory result review at a scheduled visit for a 17-year-old female JME patient on valproate — when the platform withholding her most recent LFT results, which show ALT elevated at 3× upper limit of normal since her last check 3 months ago, prevents identification of early valproate hepatotoxicity that requires immediate dose reduction and hepatology consultation, and delays the safety intervention that determines whether valproate can continue at a lower dose or whether complete medication switch to levetiracetam is indicated.
Sleep Diary and Lifestyle Trigger Management — JME Seizure Prevention
Monitor sleep diary records (nightly sleep duration records — total sleep hours; sleep onset and wake time; sleep deprivation episodes — nights with less than 7 hours sleep; delayed sleep phase pattern documentation; sleep architecture documentation for patients with sleep disorder comorbidity; school or work schedule impact on sleep adequacy), alcohol and substance diary records (alcohol consumption diary — units per week, binge drinking episodes; correlation of alcohol use with subsequent myoclonus or GTC seizures; substance use counseling records — cannabis, stimulants as seizure risk modifiers; party and social event seizure risk documentation), stress and menstrual diary records (self-reported stress level diary; academic and occupational stress period documentation; menstrual cycle diary — catamenial JME exacerbation; premenstrual myoclonus increase documentation), and school and accommodation records (school letter documentation — JME diagnosis, seizure response plan, early morning exam accommodation; university accommodation records; employer notification and occupational risk assessment records; driving restriction documentation — country-specific JME seizure-free interval requirements for driving licensure) at 1-minute intervals during clinical hours.
EEG Surveillance — 3 Hz Spike-Wave and Photoparoxysmal Response Monitoring
Monitor EEG scheduling and report records (annual EEG scheduling for CAE and JME — 3 Hz spike-wave pattern documentation; hyperventilation activation records — hyperventilation is a powerful absence seizure provocateur and EEG activation method; photoparoxysmal response testing records; medication effect on background and interictal discharge records; EEG normalization documentation as remission indicator for CAE; video-EEG records for seizure semiology confirmation), Dravet-like GABRA1 encephalopathy EEG records (prolonged EEG and video-EEG records for drug-resistant GABRA1 encephalopathy; febrile seizure EEG records — background slowing, burst suppression documentation; status epilepticus EEG records; epilepsy surgery pre-surgical evaluation EEG records for drug-resistant GABRA1 encephalopathy), and neuroimaging records (brain MRI records for GABRA1 encephalopathy — cortical malformation exclusion; corpus callosum morphology documentation; structural lesion exclusion confirming genetic etiology) at 1-minute intervals during clinical hours.
Driving Restriction and Legal Documentation
Monitor driving restriction documentation records (seizure-free interval records — continuous absence-free or GTC-free period documentation for driving eligibility; country-specific driving restriction records — reporting obligation compliance documentation; driving cessation counseling records; licence suspension notification records; driving resumption documentation after required seizure-free interval achieved; occupational driving risk documentation for commercial vehicle operators), and emergency medical information records (medical alert bracelet records — GABRA1 diagnosis, contraindicated medications; written seizure action plan documentation; emergency contact and treating physician information records; school and workplace seizure response plan records) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. GABRA1 epilepsy management coordinates across molecular genetics, pediatric and adult neurology, neurophysiology, pharmacy, and school or occupational medicine — authentication failures block the multi-specialty team at encounters where seizure diary records, valproate levels, CBC and LFT results, EEG reports, and photosensitivity documentation must all be simultaneously accessible.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, seizure diary portals, valproate monitoring systems, EEG scheduling tools, and photosensitivity management platforms. Certificate errors disrupting the seizure diary during the critical morning myoclonic period create documentation gaps for the clinical record that is the primary JME outcome measure.
HIPAA and Rare Disease Privacy Considerations for GABRA1-Related Epilepsy
GABRA1 technology platforms handle molecular genetic records (GABRA1 pathogenic variant, inheritance pattern, family cascade testing implications), seizure diary data (absence episode frequency, myoclonic jerk severity, GTC documentation with injury records), photosensitivity documentation (lifestyle exposure diary, driving restriction status), valproate prescription and laboratory monitoring records (CBC, LFT, drug levels), EEG records (3 Hz spike-wave patterns, photoparoxysmal response), driving restriction and licensing records, school and occupational accommodation documentation, and pregnancy risk counseling records across affected individuals and at-risk family members.
Alerting Strategy for GABRA1-Related Epilepsy Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: GABRA1 variant identification and syndrome classification — the diagnosis separating CAE, JME, and Dravet-like encephalopathy management pathways and establishing sodium channel blocker contraindication.
Immediate clinical-hours alerting for absence seizure diary platforms: Real-time daily absence episode counting — the primary CAE outcome measure driving ethosuximide dose adequacy decisions.
Immediate clinical-hours alerting for JME seizure diary platforms: Myoclonic jerk and GTC documentation — primary JME outcome measure and trigger pattern identification.
Immediate clinical-hours alerting for valproate safety monitoring platforms: CBC, LFT, drug level, and weight records — safety requirements for JME and GABRA1 encephalopathy treatment.
Immediate clinical-hours alerting for sodium channel blocker contraindication documentation: Carbamazepine and lamotrigine contraindication flags — patient safety requirement accessible at every prescribing encounter.
Immediate clinical-hours alerting for photosensitivity management platforms: JME visual trigger documentation — lifestyle seizure prevention compliance tracking.
Immediate clinical-hours alerting for EEG surveillance scheduling: Annual 3 Hz spike-wave and photoparoxysmal response monitoring for CAE and JME.
Sustained-failure alert (10–15 minutes): Sleep diary, lifestyle trigger records, and driving restriction documentation.
30-day advance warning: SSL certificates across all platforms.
Status Page for GABRA1 Care Team Communication
A real-time status page gives molecular genetics laboratories, pediatric and adult neurologists, neurophysiologists, clinical pharmacists, school accommodation coordinators, and rare disease registry coordinators immediate platform visibility without requiring inbound IT support contact during clinical hours.
Vigilmon Setup for GABRA1-Related Epilepsy Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | GABRA1 molecular testing and variant classification | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and family cascade testing records | 1 min | Slack + PagerDuty (lab hours) | | Absence seizure diary portal (CAE) | 1 min | Slack + PagerDuty (clinical hours) | | JME seizure diary — myoclonic and GTC records | 1 min | Slack + PagerDuty (clinical hours) | | Ethosuximide adherence and blood level monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Valproate blood level monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Valproate CBC monitoring — platelet and hepatic records | 1 min | Slack + PagerDuty (clinical hours) | | Sodium channel blocker contraindication documentation | 1 min | Slack + PagerDuty (24/7) | | Photosensitivity diary and screen exposure records | 1 min | Slack + PagerDuty (clinical hours) | | Sleep diary and lifestyle trigger records | 1 min | Slack + PagerDuty (clinical hours) | | EEG scheduling and 3 Hz spike-wave monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Driving restriction and seizure-free period records | 1 min | Slack + PagerDuty (clinical hours) | | School and occupational accommodation records | 2 min | Slack (business hours) | | GABRA1 variant registry and research enrollment | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure GABRA1 molecular testing platforms with immediate laboratory-hours alerting
- Add absence seizure diary portal with immediate clinical-hours alerting — daily absence episode counting is the primary CAE outcome measure
- Configure JME seizure diary with immediate clinical-hours alerting — myoclonic jerk and GTC documentation drives treatment and lifestyle decisions
- Add ethosuximide blood level monitoring with immediate clinical-hours alerting — therapeutic range confirmation guides CAE dose optimization
- Configure valproate blood level monitoring with immediate clinical-hours alerting
- Add valproate CBC and LFT monitoring with immediate clinical-hours alerting — hepatotoxicity and thrombocytopenia surveillance is a treatment safety requirement
- Configure sodium channel blocker contraindication documentation with 24/7 alerting — carbamazepine and lamotrigine avoidance is a patient safety requirement
- Add photosensitivity diary with immediate clinical-hours alerting — JME trigger avoidance compliance tracking
- Configure sleep diary and lifestyle trigger records with immediate clinical-hours alerting
- Add EEG scheduling with immediate clinical-hours alerting — annual 3 Hz spike-wave monitoring for CAE and JME
- Configure driving restriction records with immediate clinical-hours alerting — seizure-free period documentation is a licensing safety requirement
- Add school and occupational accommodation records with sustained-failure business-hours alerting
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to GABRA1 neurology downtime protocols, CAE absence diary procedures, and JME clinic workflows
Conclusion
GABRA1-Related Epilepsy technology platforms are embedded in clinical decisions where absence seizure diary platform availability during a CAE follow-up visit — when the pediatric neurologist must access the 30-day absence frequency trend that reveals daily episode counts declining from 22 per day at baseline to 6 per day on the current ethosuximide dose, then spiking to 18 per day in the week following a school fever illness during which the patient missed three days of medication — cannot be disrupted by seizure diary platform failures that withhold the illness-related breakthrough absence pattern at the moment when identifying medication interruption during febrile illness as the precipitant of the recent deterioration changes the entire clinical response from dose escalation to strict medication adherence counseling and fever management planning, preventing unnecessary dose increases and their associated GI side effects; where valproate safety monitoring platform availability for laboratory results at a JME follow-up — when the platform must deliver the LFT showing ALT elevation at 3× the upper limit of normal that was not present at the 3-month check, enabling the neurologist to identify early valproate hepatotoxicity and initiate the hepatology referral, valproate dose reduction, and levetiracetam transition planning that prevents progression to serious hepatic injury — cannot be disrupted by monitoring platform failures that allow hepatotoxicity to progress undetected through a missed laboratory review; and where sodium channel blocker contraindication documentation platform availability at an emergency department encounter — when the GABRA1 diagnosis record and carbamazepine contraindication flag must be accessible to the emergency physician evaluating a 14-year-old JME patient presenting with her first witnessed generalized tonic-clonic seizure — prevents the carbamazepine prescription that would aggravate GABRA1 seizures and potentially precipitate status epilepticus, making continuous contraindication documentation system availability a patient safety requirement that cannot wait for morning IT support hours.
Uptime monitoring gives GABRA1 care tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, pediatric and adult neurologists, neurophysiologists, clinical pharmacists, school coordinators, and compliance auditors that platform operational reliability matches the daily absence counting urgency, photosensitivity management requirements, and lifelong JME care coordination demands of modern GABRA1 epilepsy management.
Start monitoring your GABRA1 care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #GABRA1 #childhoodabsenceepilepsy #CAE #juvenilemyoclonicepilepsy #JME #epilepticencephalopathy #GABAA #GABAreceptor #alpha1subunit #absence #myoclonus #photosensitivity #ethosuximide #valproate #sodiumchannelblocker #contraindication #seizurediary #raredisease #channelopathy #epilepsy #HIPAA #healthtech #digitalhealth #uptime #sre